BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nakai Y, Isayama H, Sasaki T, Sasahira N, Kogure H, Hirano K, Tsujino T, Ijichi H, Tateishi K, Tada M. Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan. Jpn J Clin Oncol. 2010;40:774-780. [PMID: 20462979 DOI: 10.1093/jjco/hyq059] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Nakai Y, Isayama H, Saito K, Sasaki T, Takahara N, Hamada T, Mizuno S, Miyabayashi K, Yamamoto K, Mohri D, Kogure H, Yamamoto N, Hirano K, Ijichi H, Tateishi K, Tada M, Koike K. A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. Cancer Chemother Pharmacol 2014;74:911-5. [PMID: 25143299 DOI: 10.1007/s00280-014-2563-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
2 Takahara N, Isayama H, Nakai Y, Sasaki T, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Kogure H, Yamamoto N. A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer. Cancer Chemother Pharmacol. 2013;72:985-990. [PMID: 23995699 DOI: 10.1007/s00280-013-2278-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
3 Mie T, Sasaki T, Takeda T, Okamoto T, Mori C, Furukawa T, Yamada Y, Kasuga A, Matsuyama M, Ozaka M, Sasahira N. Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer. Jpn J Clin Oncol 2021:hyab091. [PMID: 34128055 DOI: 10.1093/jjco/hyab091] [Reference Citation Analysis]
4 Nakai Y, Isayama H, Sasaki T, Sasahira N, Tsujino T, Toda N, Kogure H, Matsubara S, Ito Y, Togawa O, Arizumi T, Hirano K, Tada M, Omata M, Koike K. A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study. Br J Cancer 2012;106:1934-9. [PMID: 22555398 DOI: 10.1038/bjc.2012.183] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 7.9] [Reference Citation Analysis]
5 Nakai Y, Isayama H, Kogure H, Hamada T, Togawa O, Ito Y, Matsubara S, Arizumi T, Yagioka H, Mizuno S, Sasaki T, Yamamoto N, Hirano K, Tada M, Koike K. Risk factors for covered metallic stent migration in patients with distal malignant biliary obstruction due to pancreatic cancer: Migration in covered metallic stent. J Gastroenterol Hepatol 2014;29:1744-9. [DOI: 10.1111/jgh.12602] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
6 Nakai Y, Isayama H, Sasaki T, Takahara N, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Yamamoto K, Mohri D. A retrospective analysis of early CA19-9 change in salvage chemotherapy for refractory pancreatic cancer. Cancer Chemother Pharmacol. 2013;72:1291-1297. [PMID: 24121456 DOI: 10.1007/s00280-013-2313-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
7 Yamamoto T, Fujii T, Hirano S, Motoi F, Honda G, Uemura K, Kitayama J, Unno M, Kodera Y, Yamaue H, Shimokawa T, Hashimoto D, Yamaki S, Yoshitomi H, Miura F, Ueno H, Sekimoto M, Satoi S; on behalf of the Study Group of Pancreatic Ductal Adenocarcinoma with Peritoneal Metastasis. Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study). Trials 2022;23. [DOI: 10.1186/s13063-022-06049-7] [Reference Citation Analysis]
8 Andrén-Sandberg A. Pancreatic cancer: chemotherapy and radiotherapy. N Am J Med Sci 2011;3:1-12. [PMID: 22540056 DOI: 10.4297/najms.2011.31] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
9 Ohmine K, Kawaguchi K, Ohtsuki S, Motoi F, Ohtsuka H, Kamiie J, Abe T, Unno M, Terasaki T. Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Free Survival of Patients Receiving Gemcitabine Treatment. Mol Pharm 2015;12:3282-91. [PMID: 26280109 DOI: 10.1021/acs.molpharmaceut.5b00282] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
10 Katsuda M, Miyazawa M, Ojima T, Katanuma A, Hakamada K, Sudo K, Asahara S, Endo I, Ueno M, Hara K, Yamada S, Fujii T, Satoi S, Ioka T, Ohira M, Akahori T, Kitano M, Nagano H, Furukawa M, Adachi T, Yamaue H. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy.Trials. 2019;20:242. [PMID: 31029154 DOI: 10.1186/s13063-019-3332-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
11 Nakai Y, Isayama H, Mukai T, Itoi T, Maetani I, Kawakami H, Yasuda I, Maguchi H, Ryozawa S, Hanada K, Hasebe O, Ito K, Kawamoto H, Mochizuki H, Igarashi Y, Irisawa A, Sasaki T, Togawa O, Hara T, Kamada H, Toda N, Hamada T, Kogure H. Impact of anticancer treatment on recurrent obstruction in covered metallic stents for malignant biliary obstruction. J Gastroenterol 2013;48:1293-9. [PMID: 23354624 DOI: 10.1007/s00535-013-0749-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
12 Yang J, Shangguan J, Eresen A, Li Y, Wang J, Zhang Z. Dendritic cells in pancreatic cancer immunotherapy: Vaccines and combination immunotherapies. Pathol Res Pract 2019;215:152691. [PMID: 31676092 DOI: 10.1016/j.prp.2019.152691] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
13 Wang M, Shi SB, Qi JL, Tang XY, Tian J. S-1 plus CIK as second-line treatment for advanced pancreatic cancer. Med Oncol 2013;30:747. [PMID: 24122257 DOI: 10.1007/s12032-013-0747-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
14 Yamane H, Kinugawa M, Umemura S, Shiote Y, Kudo K, Suwaki T, Kamei H, Takigawa N, Kiura K. An oral fluoropyrimidine agent S-1 induced interstitial lung disease: A case report. World J Clin Oncol 2011; 2(7): 299-302 [PMID: 21773080 DOI: 10.5306/wjco.v2.i7.299] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
15 Kim HJ, Yun J, Kim HJ, Kim KH, Kim SH, Lee TH, Lee SC, Bae SB, Kim CK, Lee NS. Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine-refractory pancreatic cancer patients. Oncol Lett. 2012;3:1314-1318. [PMID: 22783441 DOI: 10.3892/ol.2012.637] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
16 Lai HL, Chen YY, Lu CH, Hung CY, Kuo YC, Chen JS, Hsu HC, Chen PT, Chang PH, Hung YS, Chou WC. Effect of S-1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7-year multicenter observational cohort study in Taiwan. Cancer Med 2019;8:2085-94. [PMID: 31001907 DOI: 10.1002/cam4.2094] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
17 Saito K, Nakai Y, Takahara N, Ishigaki K, Suzuki Y, Inokuma A, Noguchi K, Kanai S, Sato T, Hakuta R, Saito T, Hamada T, Mizuno S, Kogure H, Ijichi H, Tateishi K, Koike K. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel. Invest New Drugs 2021;39:605-13. [PMID: 33094362 DOI: 10.1007/s10637-020-01022-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Kimura Y, Tsukada J, Tomoda T, Takahashi H, Imai K, Shimamura K, Sunamura M, Yonemitsu Y, Shimodaira S, Koido S. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas. 2012;41:195-205. [PMID: 21792083 DOI: 10.1097/mpa.0b013e31822398c6] [Cited by in Crossref: 87] [Cited by in F6Publishing: 46] [Article Influence: 8.7] [Reference Citation Analysis]
19 Iede K, Yamada T, Kato R, Ueda M, Tsuda Y, Nakashima S, Ohta K, Matsuyama J, Ikenaga M, Tominaga S. Predictive implications of decreased CA19-9 at 8 weeks during nab-paclitaxel plus gemcitabine for the induction of second-line chemotherapy for patients with advanced pancreatic cancer. Cancer Rep (Hoboken) 2020;3:e1289. [PMID: 32969199 DOI: 10.1002/cnr2.1289] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Takahara N, Isayama H, Nakai Y, Ishigami H, Satoi S, Mizuno S, Kogure H, Matsubara S, Yamamoto N, Yamaguchi H, Tada M, Kitayama J, Watanabe T, Koike K. Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. Invest New Drugs 2016;34:636-42. [PMID: 27339809 DOI: 10.1007/s10637-016-0369-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
21 Kawashima H, Itoh A, Ohno E, Nakamura M, Miyahara R, Ohmiya N, Hara K, Kanamori A, Itoh T, Taki T, Hirai T, Hashimoto S, Takeda K, Goto H, Hirooka Y. Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer. Cancer Chemother Pharmacol 2011;68:677-83. [DOI: 10.1007/s00280-010-1531-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
22 Takahara N, Isayama H, Nakai Y, Sasaki T, Saito K, Hamada T, Mizuno S, Miyabayashi K, Mohri D, Kogure H, Matsubara S, Yamamoto N, Hirano K, Ijichi H, Tateishi K, Tada M, Koike K. Pancreatic cancer with malignant ascites: clinical features and outcomes. Pancreas 2015;44:380-5. [PMID: 25636085 DOI: 10.1097/MPA.0000000000000290] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
23 Song H, Han B, Park CK, Kim JH, Jeon JY, Kim I, Kim HJ, Jung JY, Kim JH, Kwon JH, Jang G, Kim HY, Kim HS, Choi DR, Zang DY. Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 2013;72:845-52. [DOI: 10.1007/s00280-013-2265-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
24 Iede K, Yamada T, Kato R, Ueda M, Tsuda Y, Nakashima S, Ohta K, Matsuyama J, Ikenaga M, Tominaga S. Efficacy of S-1 in second-line chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer. Cancer Rep (Hoboken) 2020;3:e1215. [PMID: 32672000 DOI: 10.1002/cnr2.1215] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
25 Isayama H, Nakai Y, Yamamoto K, Sasaki T, Mizuno S, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Arizumi T, Togawa O, Ito Y, Matsubara S, Yamamoto N, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M, Koike K. Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer. Oncology 2011;80:97-101. [PMID: 21677453 DOI: 10.1159/000328767] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
26 Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V, Barni S. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncol 2015;54:961-70. [PMID: 25984930 DOI: 10.3109/0284186X.2015.1043026] [Cited by in Crossref: 107] [Cited by in F6Publishing: 70] [Article Influence: 15.3] [Reference Citation Analysis]
27 Takahara N, Isayama H, Nakai Y, Sasaki T, Ishigami H, Yamashita H, Yamaguchi H, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Mohri D, Kawakubo K, Kogure H, Yamamoto N, Sasahira N, Hirano K, Ijichi H, Tateishi K, Tada M, Kitayama J, Watanabe T, Koike K. Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. J Gastrointest Cancer 2014;45:307-11. [PMID: 24676891 DOI: 10.1007/s12029-014-9603-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
28 Takahara N, Nakai Y, Isayama H, Sasaki T, Satoh Y, Takai D, Hamada T, Uchino R, Mizuno S, Miyabayashi K. Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer. Cancer Chemother Pharmacol. 2013;71:85-92. [PMID: 23053265 DOI: 10.1007/s00280-012-1981-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
29 Ikagawa M, Kimura M, Iwai M, Usami E, Yoshimura T, Yasuda K. Neutropenia as a prognostic factor and safety of second-line therapy with S-1 for advanced or recurrent pancreatic cancer. Mol Clin Oncol 2016;5:283-8. [PMID: 27588194 DOI: 10.3892/mco.2016.940] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]